Aurobindo Accelerates Biosimilars Efforts With Second Filing

As Company Makes Seven Drug Launches in Q3 FY22

 
• By Akriti Seth
Drug Development
Aurobindo focuses on developing oncology and immunology biosimilars • Source: Alamy

More from Strategy

More from Business